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ABSTRACT
Background: IRF5 is a transcription factor involved both
in the type I interferon and the toll-like receptor signalling
pathways. Previously, IRF5 has been found to be
associated with systemic lupus erythematosus, rheuma-
toid arthritis and inflammatory bowel diseases. Here we
investigated whether polymorphisms in the IRF5 gene
would be associated with yet another disease with
features of autoimmunity, multiple sclerosis (MS).
Methods: We genotyped nine single nucleotide poly-
morphisms and one insertion-deletion polymorphism in
the IRF5 gene in a collection of 2337 patients with MS
and 2813 controls from three populations: two case–
control cohorts from Spain and Sweden, and a set of MS
trio families from Finland.
Results: Two single nucleotide polymorphism (SNPs)
(rs4728142, rs3807306), and a 5 bp insertion-deletion
polymorphism located in the promoter and first intron of
the IRF5 gene, showed association signals with values of
p,0.001 when the data from all cohorts were combined.
The predisposing alleles were present on the same
common haplotype in all populations. Using electro-
phoretic mobility shift assays we observed allele specific
differences in protein binding for the SNP rs4728142 and
the 5 bp indel, and by a proximity ligation assay we
demonstrated increased binding of the transcription factor
SP1 to the risk allele of the 5 bp indel.
Conclusion: These findings add IRF5 to the short list of
genes shown to be associated with MS in more than one
population. Our study adds to the evidence that there
might be genes or pathways that are common in multiple
autoimmune diseases, and that the type I interferon
system is likely to be involved in the development of these
diseases.
Multiple sclerosis (MS, OMIM 126200) is an
inflammatory disease estimated to affect over
two million individuals worldwide. MS is not well
recognised as an autoimmune disease, but exhibits
features of autoimmunity—that is, activation of
the immune system in the absence of apparent
ongoing infection.
1 In MS the presumed target for
the autoimmune process is the central nervous
system, and the disease manifests itself by immune
mediated demyelination and damage to axons. A
spectrum of neurological symptoms are found
among MS patients, including sensory or motor
pareses, visual disturbances, ataxia, pain, cognitive
dysfunction and fatigue. MS is a complex disease
caused by interaction between environmental and
inherited factors. The disease shows familial
clustering, and twin studies have revealed that a
large portion of this clustering can be attributed to
shared genes.
2
A remarkably low number of susceptibility genes
for MS have been identified so far. Genome-wide
linkage studies have indicated several possible
susceptibility loci, but the only locus to be
identified across most studies is the major histo-
compatibility complex (MHC) on chromosome
6p21, were the HLA-DRB1*1501 allele is a well
established genetic risk factor for MS.
34This locus
does not, however, account for the whole genetic
component of MS, and multiple loci with smaller
contributions to disease susceptibility are likely to
exist. Numerous candidate gene studies have also
been performed in MS, but findings from one
population have been difficult to replicate in other
populations. The protein kinase C a (PRKCA) gene
is one of few genes reported to be associated with
MS in more than one population.
56Recently, the
interleukin 7 receptor a chain gene (IL7RA) was
found to be associated with MS in two indepen-
dent candidate gene studies and in a genome-wide
association study.
7–9 The genome-wide association
study also identified variants in the interleukin 2
receptor a chain gene (IL2RA) as risk factors for
MS,
7 which is in accordance with findings in a
previous candidate gene study.
10
It is relatively common that patients affected by
an autoimmune disease suffer from another auto-
immune disease, and that members of the same
family suffer from different autoimmune diseases.
For example, in families with systemic lupus
erythematosus (SLE, OMIM 152700), MS and
rheumatoid arthritis (RA, OMIM 180300) occur
more frequently than in the general population.
11
Such observations suggest shared genes or involve-
ment of common cellular pathways in these
diseases. This hypothesis is supported by reports
on genes found to be associated with more than
one autoimmune disease in experimental models of
RA and MS.
12 Shared genes in autoimmune
diseases are becoming apparent also in humans,
such as PTPN22 in RA and SLE,
13 MHC2TA in RA
and MS,
14 and recently the suggested involvement
of CD24 in MS and SLE.
15
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play a key role in autoimmune diseases.
16 Increased expression
of IFN induced genes has been detected in autoimmune diseases
like SLE,
17 RA,
18 Sjo ¨gren’s syndrome,
19 and in a subgroup of MS
patients.
20 The interferon regulatory factors (IRFs) are major
regulators of genes activated by the type I IFNs,
21 and a role in
the regulation of the immune system is well established for the
majority of the members of the IRF family of nine genes. The
role of IRF5 in the immune response is not as well established as
for other IRFs, but IRF5 has recently received attention in
studies on autoimmunity. The IRF5 gene displays a complex
transcription pattern with three alternative non-coding 59 exons
and at least nine alternatively spliced mRNAs.
22 IRF5 is
expressed in dendritic cells, monocytes and B cells, but its
expression can be induced in other cell types by the type I
IFNs.
23 IRF5 regulates the toll-like receptor (TLR) dependent
activation of inflammatory cytokines and functions down-
stream of the TLR-MyD88 pathway where it is activated by
MyD88 and TNF receptor associated factor 6 (TRAF6).
24 Our
original finding of an association between the IRF5 gene and
SLE,
25 which has been replicated in multiple populations, as well
as our recent findings of association between IRF5 and RA
26 and
inflammatory bowel diseases (IBD),
27 provide additional support
for the important role of IRF5 and the type I IFN system in
autoimmune diseases. Inspired by these findings, and by the role
of recombinant IFN b as a standard treatment of MS, we
investigated whether polymorphisms in the IRF5 gene would
also be associated with MS. We found that polymorphisms in
the IRF5 gene displayed associations with MS in three
independent patient cohorts from Spain, Sweden and Finland.
The three most strongly associated polymorphisms are located
in the promoter region and first intron of IRF5. A functional role
is suggested by increased protein binding to the risk alleles of
two of these polymorphisms.
PATIENTS AND METHODS
Clinical samples
Cohorts of MS patients collected in Spain, Sweden and Finland
were included in the study. All patients had clinically or
laboratory supported definite MS according to the Poser
criteria
28 or fulfilled the criteria of McDonald for MS.
29 In total
660 Spanish MS patients were recruited at three public hospitals
in the south of Spain: Clı ´nico in Granada (n=130), Carlos Haya
in Ma ´laga (n=363) and Virgen de la Macarena in Seville
(n=167). The Spanish controls were 833 blood donors without
history of inflammatory disease attending the blood banks of
Granada (n=441), Seville (n=211) and Ma ´laga (n=181); 67%
of the patients and 50% of the controls were female. The
Swedish cohort consisted of 1166 MS patients (67% females)
and 1235 controls (63% females) of Nordic ethnicity recruited at
Danderyd’s Hospital or Karolinska University Hospital in
Huddinge or in Solna, all located in the Stockholm County of
Sweden. Controls were consecutive blood donors of Nordic
origin that visited three blood donor facilities in the Stockholm
area in 2001 and in 2004/2005. The Finnish cohort consisted of
511 MS trio-families recruited at five centres in Finland: the
University Central Hospitals in Helsinki (n=148 families),
Tampere (n=102), Kuopio (n=79), Oulu (n=73), and the
Central Hospital of Seina ¨joki (n=109); 71% of the Finnish
patients were female. The study was approved by the respective
local ethics committees and informed consent was obtained
from all study participants.
Genotyping
Nine single nucleotide polymorphisms (SNPs) and one 5 bp bi-
alleic insertion-deletion polymorphism (CGGGG indel) in the
IRF5 gene were genotyped. The SNPs were genotyped using
multiplex fluorescent minisequencing (single base extension)
with the SNPstream system (Beckman Coulter).
30 The SNP
rs4728142 was also genotyped using a homogeneous minise-
quencing assay with fluorescence polarisation detection (FP-
TDI) (Analyst AD, Molecular Probes) in 1440 Swedish samples.
The genotype call rate in the samples was on average 96.6% and
the genotyping accuracy was 99.8% as estimated from 13.800
genotype comparisons (20% of the genotypes) between repeated
assays. The CGGGG indel was amplified as a 100/105 bp
polymerase chain reaction (PCR) fragment using fluorescent
primers with subsequent fragment analysis on an ABI PRISM
3730 DNA Analyzer (Applied Biosystems, Foster City,
California, USA). The GeneMapper v.3.7. software was used
for genotype calling. Alternatively, the PCR amplified fragments
were separated on 4% MetaPhor high resolution agarose gels
(Cambrex Bio Science Rockland Inc, Maine, USA) and visualised
using ethidium bromide staining. The call rate for genotyping
the CGGGG indel was on average 96.0% in the three cohorts
and the genotyping accuracy was 99.1% as estimated from
genotype comparison between repeated assays for 15% of the
subjects. Samples with a genotype call rate ,80% for the 10
markers and four trios with inheritance errors were excluded
from the analysis. The PCR and extension primers are provided
Figure 1 Schematic illustration of the IRF5 gene with the positions of the analysed polymorphisms. The exons and the 39-UTR are shown as boxes
with the exons labelled 1-9 and the untranslated alternative exons in the 59-end of IRF5 labelled as 1a, 1b and 1c. The translation initiation site is
indicated by an arrow above the gene. The single nucleotide polymorphism (SNP) rs2004640 is located at the splice junction of alternative exon 1b,
where it alters a consensus splice donor site that allows expression of IRF5 mRNA containing exon 1b.
38 The SNP rs10954213 located in the
39untranslated region (UTR) of the gene correlates with an altered length of the IRF5 39UTR and thereby affects the stability of the IRF5 transcript.
35 The
SNPs rs2280714, located ,6 kb downstream of the IRF5 gene, has been reported to be correlated with variation in IRF5 mRNA expression levels.
35 37 A
5 bp insertion-deletion polymorphism (CGGGG indel) in the promoter regiono fIRF5, identified by sequencing the IRF5 gene in Swedish individuals,
35
was included in our study because it is predicted to alter a binding site for the transcription factor SP1, which could affect the expression of IRF5. The
SNP rs 12539741 was included because this SNP, and several other SNPs located 39 of IRF5 that are in almost full linkage disequilibrium (LD) with it,
show very strong association signals with systemic lupus erythematosus.
35
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fulfilled the criteria of Hardy–Weinberg equilibrium in the
control samples.
Electrophoretic mobility shift assay (EMSA)
For each allele of the polymorphism, pairs of single stranded 59
biotinylated and unlabelled 30–37 bp oligonucleotides (obtained
from IDT Inc, Coralville, Iowa, USA) were allowed to anneal to
generate double stranded probes (supplementary table S2).
Twenty fmoles of labelled probes was incubated for 20 min
with 2 ml of nuclear extract prepared from blood cells in a
freshly made binding buffer supplemented with poly(dI-
dC)?poly(dI-dC) and protease inhibitors. Competition experi-
ments were performed using a 100-fold molar excess of
unlabelled probe. The binding reactions were analysed using
electrophoresis on 6% polyacrylamide gels and transferred to
nylon membranes (Bio-Rad Laboratories, Hercules, California,
USA). The biotinylated fragments were detected by a chemi-
luminescent procedure (LightShift Chemiluminescent EMSA
kit, Pierce Biotechnology, Rockford, Illinois, USA).
Proximity ligation assay (PLA)
Polyclonal antibody against SP1 was purchased from Santa
Cruz Biotechnology (Cat. no. sc-14027, Santa Cruz, California,
USA). The antibody was biotinylated using D-biotin-N-
hydroxysuccinimide (Nordic Biosite, Ta ¨by, Sweden) according
to the recommendation by the manufacturer. The biotinylated
antibody was diluted in phosphate buffered saline (PBS)
containing 1% bovine serum albumin (BSA) to a final
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Table 2 Association analysis of IRF5 polymorphisms with multiple
sclerosis in the Finnish trios
Polymorphism Associated allele Obs-Exp* p Value
rs729302 A + 0.047
rs4728142 A + 0.035
rs3757385 G + 0.53
CGGGG indel in + 0.056
rs2004640 T + 0.54
rs3807306 T + 0.012
rs10954213 A + 0.010
rs11770589 A + 0.070
rs2280714 T + 0.30
rs12539741 T + 0.74
*Difference between observed and expected transmissions of the associated allele; +
denotes increased transmission to affected offspring; p values below 0.05 are
indicated in bold.
Table 3 Combined association analysis of IRF5 polymorphisms with
multiple sclerosis in three cohorts
Polymorphism
Spanish c/c* Swedish c/c* Finnish trios
Combined
p value p Value p Value p Value
rs729302 0.22 0.29 0.047 0.07
rs4728142 0.0029 0.020 0.035 0.0002
rs3757385 0.0052 0.43 0.53 0.04
CGGGG indel 0.011 0.0093 0.056 0.0005
rs2004640 0.0011 0.082 0.54 0.003
rs3807306 0.0037 0.049 0.012 0.0002
rs10954213 0.031 0.15 0.010 0.003
rs11770589 0.29 0.49 0.070 0.16
rs2280714 0.0030 0.43 0.30 0.02
rs12539741 0.074 0.10 0.74 0.11
*c/c denotes case–control; p values below 0.05 are indicated in bold.
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combined in a 1:1 ratio with a streptavidin–oligonucleotide
conjugate (SoluLink, San Diego, California, USA) in a volume of
20 ml, incubated at room temperature for 1 h, and then stored at
4uC until use. High pressure liquid chromatography (HPLC)
purified DNA probes (Biomers.net, Ulm, Germany) were made
partially double stranded according to Gustafsdottir et al.
31 The
partially double stranded DNA probes (25 pM) were incubated
with 200 ng of Jurkat nuclear extract (Active Motif, Carlsbad,
California, USA) in PBS containing 1% BSA, 16 mg/ml of
sheared polyA bulk nucleic acid (Sigma-Aldrich, Stockholm,
Sweden), 1 mM D-biotin (Molecular Probes, Eugene, Oregon,
USA) in a total volume of 9 ml for 30 min at room temperature;
6 ml of 25pM anti-SP1-DNA conjugate was added to the
mixture, and the incubation was continued for 2 h at 20uC.
After the incubations, 35 ml of a combined mixture for ligation
and real-time PCR amplification/detection was added. Ligation
and PCR amplification/detection was performed according to
Gustafsdottir et al.
31 Sequences of the primers, probes and the
streptavidin–oligonucleotides used in PLA are provided in
supplementary table S2.
Statistical analysis
A x
2 test (p.0.05) was used to assess that the genotype
distributions of the polymorphisms fulfilled the criteria of
Hardy–Weinberg equilibrium. The PLINK software (http://
pngu.mgh.harvard.edu/,purcell/plink/) was used to compare
the allele counts in cases and controls by Fisher’s exact test and
to calculate odds ratios (OR) with 95% confidence intervals.
PLINK was also used to perform the sliding window haplotype
association analysis. The Haploview v.3.3. software was used to
determine linkage disequilibrium (LD) between the polymorph-
isms. In the family cohort, the genotype data were analysed
using the TRANSMIT 2.5.2. computer program package.
32
Alleles that were included in the analysis were required to be
transmitted from a least 20 informative meioses, corresponding
to the Var (O-E) value of 5 or more in the TRANSMIT analysis.
A combined p value from case–control cohorts and trios were
calculated using the analytical expression by Jost, k(1-(ln(k))+(-
ln(k)
2)/2), where k is the product of the p values from the
different cohorts (http://www.loujost.com). This formula is an
analytical solution of Fischer’s original formula for combining p
values.
33 The ssSNPer tool was used to determine the pair-wise
correlation between SNPs in the HapMap data.
34
RESULTS
Ten polymorphisms in the IRF5 gene on chromosome 7q32
were genotyped in MS patient samples collected in three
European countries. The selected polymorphisms include five
SNPs and one insertion-deletion polymorphism (indel) in the
promoter region or first intron of IRF5, two SNPs in the 39UTR
and two SNPs downstream of IRF5 (fig 1). The polymorphisms
were selected because they have previously been shown to be
associated with SLE,
25 35 36 RA
26 and IBD,
27 or have been
suggested to modulate the expression of IRF5.
35–38
The polymorphisms were first genotyped in a Spanish cohort
of MS patients (n=660) and controls (n=833). Seven of the 10
polymorphisms showed nominally significant signals of associa-
tion with MS (p,0.05) (table 1). To replicate this finding, we
genotyped the same set of polymorphisms in an independent
case–control cohort with 1166 MS patients and 1235 matched
controls from Sweden. Two of the SNPs, rs4728142 and
rs3807306, and the CGGGG indel polymorphism, showed a
nominally significant association (p,0.05) with MS. Each of
these three polymorphisms was also associated with MS in the
Spanish samples (table 1). In a further attempt to verify these
findings from two case–control cohorts of MS patients, we
genotyped the same set of polymorphisms in 511 Finnish MS
trio families. Using a transmission disequilibrium test, four
polymorphisms showed nominally significant association with
MS (table 2). Two SNPs, rs4728142 and rs3807306, were
nominally significantly associated with MS in all three cohorts
(tables 1 and 2).
Information on HLA-DRB1*15 genotype was available from
the Swedish cases and controls, and from the Finnish patients
(supplementary table S3). In the Swedish dataset most of the
association signal was observed in the DR15-negative stratum,
whereas in the Finnish dataset the DR2 stratum provided most
of the association signal (supplementary table S4). When
combining the p values from all cohorts, seven of the 10
polymorphisms exhibited association with MS with p values
ranging from 0.0002 to 0.04. The strongest association signals in
this combined analysis were observed for the SNP rs4728142
(p=0.0002) located ,5 kb upstream of IRF5, the CGGGG indel
located 64 bp upstream of exon 1a of IRF5 (p=0.0005), and the
SNP rs3807306 in the first intron of IRF5 (p=0.0002) (table 3,
fig 1).
The linkage disequilibrium (LD) pattern of the polymorph-
isms was similar between the three populations (figure 2), and
displayed relatively high LD with pair-wise r
2 values of 0.61–
0.88 for the three associated polymorphisms in the Spanish,
Swedish and Finnish unaffected subjects. We performed
haplotype association tests in the three populations to
investigate whether haplotypes could capture the association
signal at a higher significance than the individual polymorph-
isms, and whether all three populations harbour the same
disease associated haplotype(s). The haplotype analysis was
performed using a five marker sliding window approach. The
associated risk alleles of the polymorphisms were all present on
Figure 2 Linkage disequilibrium (LD)
structure of the IRF5 gene. Pairwise r
2
values are shown for controls or founders
in the Spanish, Swedish and Finnish
cohorts, respectively. The three most
strongly associated markers rs4728142,
the CGGGG indel and rs3807306 are in
relatively high LD with each other with
pair-wise r
2 values .0.6.
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0.51 and was the same in all three cohorts (table 4). The
association signals were comparable to those in the analysis of
individual polymorphisms.
We used electrophoretic mobility shift assays (EMSA) to test
for differential protein binding to the alleles of the three
polymorphisms rs4728142, rs3807306 and the CGGGG indel,
which displayed association signals with values of p,0.001 in
the combined analysis of the three MS cohorts. This analysis
revealed a stronger binding of protein to the risk alleles of the
SNP rs4728142 (the A allele) and of the CGGGG indel
polymorphism (the 46CGGGG allele) (fig 3). For the CGGGG
indel polymorphisms the insertion of one CGGGG repeat in the
longer (46CGGGG) allele is predicted to create an additional
and third binding site for the transcription factor SP1, while the
shorter (36CGGGG) allele has two SP1 binding sites
(TFSEARCH: http://www.cbrc.jp/research/db/TFSEARCH.
html).
39 By using the proximity ligation assay
31 40 we confirmed
that SP1 protein binds to the alleles of the CGGGG indel, and
that an increased amount of SP1 is bound to the 46CGGGG
allele than to the 36CGGGG allele of the indel polymorphism
(fig 4).
DISCUSSION
Here we describe the association of three polymorphisms in the
IRF5 gene with MS in three independent patient cohorts from
Spain, Sweden and Finland. The SNPs rs4728142 and rs3807306
reached nominal significance for association in all cohorts and
revealed strong signals of association with MS (p=0.0002)
when the data from all three cohorts was combined. The SNP
rs4728142 is located ,5 kb upstream of the alternative exon 1a
of IRF5, and rs3807306 is located in the first intron of the gene,
96 bp upstream of alternative exon 1c (fig 1). The SNP
rs3807306 was the only IRF5 polymorphism reported in the
recently performed genome-wide association study on MS.
7 In
that study the SNP rs3807306 exhibited association with MS
with a TDT p value of 0.014 (https://imsgc.org/), but it did not
pass the threshold for inclusion in the confirmatory phase of the
study. This study also identified the T allele as the risk allele. It
is notable that the initial TDT screening phase of this genome-
wide study only had about 6% power to detect each locus at the
chosen cut off and with the observed modest risk ratios.
7 The
effect of this low power becomes apparent when looking at the
SNPs in IL2RA and IL7RA, which did not pass the initial p value
cut off for the TDT, but turned out to be the most strongly
associated markers after the replication phase. In our study the
CGGGG indel polymorphisms, located 64 nucleotides upstream
of the alternative exon 1a of IRF5, also showed evidence of
association with MS. Although the CGGGG indel did not reach
statistical significance independently in all three cohorts, the
combined analysis revealed a clear association signal between
the CGGGG indel and MS (p=0.0005), with the longer allele
(46CGGGG) as the risk allele.
The risk alleles of the SNPs rs4728142 and rs3807306 and of
the CGGGG indel are present on the same common haplotype
in each of the three populations (table 4). In a recent study on
IBD we analysed the same set of polymorphisms as in the
current study on MS, and found that the same three
polymorphisms were associated with IBDs, with the strongest
signal of association for the CGGGG indel.
27 We have recently
performed an association study of a comprehensive set of
polymorphisms in IRF5 that were identified by sequencing the
introns and exons of IRF5 in SLE patients.
41 This analysis
identified a set of correlated polymorphisms in IRF5 that gave
strong signals of association with SLE (p,10
-6), including the
SNPs rs4728142, and rs3807306 and the CGGGG indel. In SLE
logistic regression analysis conditional only on the CGGGG
indel abolished all the other association signals from this set of
correlated SNPs. Because the effect size of the polymorphisms
are lower in MS than in SLE we cannot distinguish which one of
them would be the most likely causal variant in MS. In an
earlier association study on RA we analysed five SNPs in IRF5,
including the SNPs rs729302, rs375385, rs 2004640 and 3807306,
Figure 3 Electrophoretic mobility shift
assay images for the three most strongly
associated variants of IRF5. Reactions
loaded in lanes 1–4 (from left to right) for
each allele contain: (1) labelled probe
only; (2) labelled probe and nuclear
extract; (3) labelled probe, nuclear extract
and the unlabeled probe, which is added
as a competitor in 100-fold excess; (4)
labelled probe, nuclear extract, and a 100-
fold excess of unlabelled probe for the
other allele of the polymorphism added as
a cross-competitor.
Figure 4 Result from analysis of the SP1 protein–promoter interaction
using the proximity ligation assay. The probes included in the assay
shown from left to right are: SP1 mut—negative control probe where
four nucleotides within the SP1 consensus binding site have been
altered; CGGGG indel 36and 46—probes with three or four copies of
CGGGG; SP1—positive control probe with SP1 consensus binding site;
No lysate—control reaction where no nuclear lysate was added to the
reaction. The samples were analysed in duplicate and the result
presented are mean values of signal/noise, where the signal from the
proximity probe pairs in the sample is divided by the signal in the control
reaction without cell lysate. The data shown are from a representative
experiment repeated three times with similar results. In each individual
experiment the signal obtained by the 46CGGGG indel probe was
2.6¡0.3 fold higher than the signal from the 36CGGGG indel probe.
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association with RA for the SNP rs3807306.
26 Taken together,
the association results from the current study on MS and
previous studies on IBD, SLE and RA indicate that one or more
of these correlated polymorphisms in the promoter and first
intron of the IRF5 gene could be a universal risk factor for
chronic inflammatory disorders, but further studies are required
to dissect if the mechanism is the same in all of these disorders.
Using EMSA, as a preliminary functional test for the three
polymorphisms in IRF5 that gave the strongest association
signals with MS, we observed stronger protein binding to the
risk alleles of the SNP rs4728142 (the A allele) and of the
CGGGG indel polymorphisms (the 46CGGGG allele), whereas
both alleles of the SNP rs3807306 appear to bind an equal
amount of protein. We confirmed experimentally using an
antibody against SP1 in the proximity ligation assay
31 that an
increased amount of transcription factor SP1 binds to the risk
allele (the 46CGGGG allele) of the CGGGG indel polymorph-
ism. This result is also supported indirectly by a study in which
they demonstrated that SP1 binds to a similar sequence motif in
the IRF1 and IRF4 genes.
42 43
It is notable that the SNP rs12539741 located in the 39-end of
the IRF5 gene does not show any association with MS in our
study. In SLE this SNP and two other linked SNPs, the SNPs
rs2070197 in the 39-UTR of IRF5 and rs10488631 located ,5k b
downstream of IRF5, give particularly strong association
signals.
35 Two recent genome-wide association studies failed
to detected an association with RA for the SNP rs10488631 or
its proxies
44 45 and in our study on IBD we did not detect an
association with the SNP rs10488631 either.
27 Thus it appears
that in SLE there are two groups of independently associated
polymorphisms in the IRF5 gene region,
46 whereas in MS, RA
and IBD association from only one of these groups is observed.
According to data from the HapMap project (www.hapmap.
org), the SNP rs10488631 is in complete LD with multiple SNPs
located in a 100 kb region downstream of IRF5, which also
contains the transportin 3 (TNPO3) gene. The polymorphisms
in the IRF5 gene that we found to be associated with MS in our
study are not strongly correlated (r
2 0.1–0.2) with the SNP
rs10488631 or its proxies in the TNPO3 gene,
34 indicating that it
actually is IRF5, and not TNPO3, that is primarily responsible
for the association with MS that we observe.
Three different European populations were included in the
present study, and the observed allele and haplotype frequencies
did not show major inter-population differences. The disease
predisposing alleles are the same and occur on the same major
haplotype in the Spanish, Swedish and Finnish populations.
These results indicate that the predisposing alleles are widely
distributed in the Caucasian population. The effect sizes of the
risk alleles are relatively small, with odds ratios of about 1.2,
indicating that large datasets are needed to replicate these
findings. The strength of our study is that we used both case–
controls and family based association testing. Population
stratification artefacts are common in case–control settings,
but unlikely in family based studies.
47 On the other hand, the
TDT may be biased by erroneous detection of association to
alleles with high frequency in the analysed populations.
48
MS is a common disease, and most likely caused by
interaction between multiple common allelic variants of genes.
The association of IRF5 polymorphisms with MS in the cohorts
studied here suggests that IRF5 is one of these genes that
contribute to the disease. Interestingly, in the animal models for
MS, experimental autoimmune encephalomyelitis, deletion of
the IFN b gene leads to more severe disease,
49 suggesting that the
inherent type I IFN function contributes to the autoimmune
disease. Currently, the most common therapy in MS is IFN b,
which has been shown to reduce the magnetic resonance
imaging activity and relapse rate in MS. This therapeutic effect
is consistent with an immunoregulatory role of the type I IFN
pathway in MS. The findings from our study add IRF5 to the
short list of genes with confirmed association with MS. Our
study also contributes to the evidence that there might be genes
or pathways that are common between multiple autoimmune
diseases, and that the type I IFN signalling system, to which the
IRF5 gene belongs, is likely to be one of these pathways.
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